Skip to content

This website is a third-party information service. It does not provide medical care or operate a treatment facility.

CNS Medication Trials

Anaheim, California

CNS medication trials in Anaheim, CA

25 CNS medication studies are recruiting participants at sites in Anaheim as of November 17, 2026, according to ClinicalTrials.gov. CNS Medication Trials can help you understand your options and connect with a study team.

Call (888) 927-5768
  • No cost to ask
  • Taking part is voluntary
  • Studies are independently reviewed

Anaheim at a glance

  • 25 studies are recruiting at a site in Anaheim.
  • By phase: Phase 1 (1), Phase 2 (5), Phase 3 (18), Phase 4 (1).
  • By sponsor: industry (25).
  • By research area: Schizophrenia (9), Depression (6), Migraine (5), ADHD (3), Bipolar Disorder (2).
  • Most recent update to one of these records: November 12, 2026.

Depression studies recruiting in Anaheim

Basic details from each study's public record. Select a study to read the full record on ClinicalTrials.gov, including how to contact its team.

  1. Multicenter Study of Lumateperone for the Treatment of Bipolar Depression in Pediatric Patients

    • Phase 3
    • Ages 10 to 17
    • All sexes
    Sponsor
    Intra-Cellular Therapies, Inc.
    Study site
    Advanced Research Center, Inc
    Registry record
    NCT06372964 · updated
  2. Phase 3 Study of Adjunctive Treatment With Seltorexant in Adult and Elderly Participants With Major Depressive Disorder and Insomnia Symptoms

    • Phase 3
    • Ages 18 to 74
    • All sexes
    Sponsor
    Janssen Research & Development, LLC
    Study site
    PAMOJA Clinical Institute LLC
    Registry record
    NCT06559306 · updated
  3. A Study to Assess Adverse Events and Change in Disease Activity of Oral Icalcaprant in Adult Participants With Bipolar I or II Disorder

    • Phase 2
    • Ages 18 to 65
    • All sexes
    Sponsor
    AbbVie
    Study site
    Advanced Research Center /ID# 272828
    Registry record
    NCT06696755 · updated
  4. A Study to Assess Change in Disease Activity and Adverse Events (AEs) With Cariprazine in the Treatment of Depressive Episodes in Pediatric Participants Participants (10 to 17 Years of Age) With Bipolar I Disorder.

    • Phase 3
    • Ages 10 to 17
    • All sexes
    Sponsor
    AbbVie
    Study site
    Advanced Research Center /ID# 227073
    Registry record
    NCT04777357 · updated
  5. A Study to Assess Change in Disease Activity and Adverse Events of Oral Icalcaprant in Adult Participants With Major Depressive Disorder

    • Phase 2
    • Ages 18 to 65
    • All sexes
    Sponsor
    AbbVie
    Study site
    Advanced Research Center /ID# 277537
    Registry record
    NCT07276997 · updated
  6. Study of ABX-002 for the Adjunctive Treatment of Major Depressive Disorder (AMPLIFY)

    • Phase 2
    • Ages 18 to 65
    • All sexes
    Sponsor
    Autobahn Therapeutics, Inc.
    Study site
    Autobahn Site #150
    Registry record
    NCT06633016 · updated

Source: ClinicalTrials.gov. Data processed . See every depression study recruiting in Anaheim, CA on ClinicalTrials.gov.

Schizophrenia studies recruiting in Anaheim

  1. A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Alzheimer's Disease Psychosis

    • Phase 2
    • Ages 55 to 90
    • All sexes
    Sponsor
    MapLight Therapeutics
    Registry record
    NCT06887192 · updated
  2. A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Schizophrenia in Adolescents (EMERGENT TEEN)

    • Phase 3
    • Ages 13 to 17
    • All sexes
    Sponsor
    Bristol-Myers Squibb
    Study site
    Advanced Research Center Inc.
    Registry record
    NCT07288567 · updated
  3. A Study to Evaluate the Long-term Safety and Tolerability of Xanomeline and Trospium Chloride for the Treatment of Psychiatric Disorders in Children and Adolescents

    • Phase 3
    • Ages 5 to 17
    • All sexes
    Sponsor
    Karuna Therapeutics, Inc., a Bristol Myers Squibb company
    Study site
    Advanced Research Center Inc.
    Registry record
    NCT07424404 · updated
  4. Safety and Tolerability Trial of Lumateperone in Pediatric Patients With Schizophrenia, Bipolar Disorder or Autism Spectrum Disorder

    • Phase 3
    • Ages 5 to 17
    • All sexes
    Sponsor
    Intra-Cellular Therapies, Inc.
    Study site
    Advanced Research Center, Inc
    Registry record
    NCT06229210 · updated
  5. A Study to Assess the Efficacy and Safety of ITI-1284 in the Treatment of Psychosis Associated With Alzheimer's Disease

    • Phase 2
    • Ages 55 and older
    • All sexes
    Sponsor
    Intra-Cellular Therapies, Inc.
    Study site
    Advanced Research Center, Inc
    Registry record
    NCT06540833 · updated
  6. A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)

    • Phase 3
    • Ages 55 to 90
    • All sexes
    Sponsor
    Karuna Therapeutics, Inc., a Bristol Myers Squibb company
    Study site
    Advanced Research Center, Inc.
    Registry record
    NCT06585787 · updated
  7. 52-week Open Label Safety-Tolerability Study

    • Phase 3
    • Ages 18 to 65
    • All sexes
    Sponsor
    LB Pharmaceuticals Inc.
    Study site
    Advanced Research Center
    Registry record
    NCT07369154 · updated
  8. Determining Efficacy and Safety of BXCL501 in Agitation Associated With Pediatric Schizophrenia and Bipolar Disorder

    • Phase 1
    • Ages 10 to 17
    • All sexes
    Sponsor
    BioXcel Therapeutics Inc
    Study site
    BioXcel Clinical Research Site
    Registry record
    NCT05025605 · updated
  9. NBI-1117568-SCZ3029: Evaluation of NBI-1117568 in Inpatient Adults With Schizophrenia

    • Phase 3
    • Ages 18 to 65
    • All sexes
    Sponsor
    Neurocrine Biosciences
    Study site
    Neurocrine Clinical Site
    Registry record
    NCT06963034 · updated

Source: ClinicalTrials.gov. Data processed . See every schizophrenia study recruiting in Anaheim, CA on ClinicalTrials.gov.

Bipolar disorder studies recruiting in Anaheim

  1. A Study to Assess the Long-term Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-3)

    • Phase 3
    • Ages 18 to 65
    • All sexes
    Sponsor
    Bristol-Myers Squibb
    Study site
    Advanced Research Center Inc.
    Registry record
    NCT06929273 · updated
  2. A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder

    • Phase 3
    • Ages 18 to 65
    • All sexes
    Sponsor
    Bristol-Myers Squibb
    Study site
    Advanced Research Center Inc.
    Registry record
    NCT06951698 · updated

Source: ClinicalTrials.gov. Data processed . See every bipolar disorder study recruiting in Anaheim, CA on ClinicalTrials.gov.

ADHD studies recruiting in Anaheim

  1. Forward Treatment of Attention Deficit and Hyperactivity Using Solriamfetol (FOCUS-2)

    • Phase 3
    • Ages 6 to 11
    • All sexes
    Sponsor
    Axsome Therapeutics, Inc.
    Registry record
    NCT07717879 · updated
  2. Forward Treatment of Attention Deficit and Hyperactivity Using Solriamfetol (FOCUS-3)

    • Phase 3
    • Ages 12 to 17
    • All sexes
    Sponsor
    Axsome Therapeutics, Inc.
    Registry record
    NCT07717892 · updated
  3. Evaluation of SPN-812 (Viloxazine Extended-release Capsule) in Preschool-age Children With ADHD

    • Phase 4
    • From 48 months, up to 69 months
    • All sexes
    Sponsor
    Supernus Pharmaceuticals, Inc.
    Study site
    Advanced Research Center (ARC), Inc.
    Registry record
    NCT04781140 · updated

Source: ClinicalTrials.gov. Data processed . See every ADHD study recruiting in Anaheim, CA on ClinicalTrials.gov.

Migraine studies recruiting in Anaheim

  1. Randomized Study in Children and Adolescents With Migraine: Acute Treatment

    • Phase 3
    • Ages 6 to 17
    • All sexes
    Sponsor
    Pfizer
    Study site
    Advanced Research Center, Inc.
    Registry record
    NCT04649242 · updated
  2. Long-term Safety Study of Rimegepant in Pediatric Subjects for the Acute Treatment of Migraine

    • Phase 3
    • Ages 6 to 17
    • All sexes
    Sponsor
    Pfizer
    Study site
    Advanced Research Center, Inc.
    Registry record
    NCT04743141 · updated
  3. A Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Disease Activity To Prevent Migraine in Participants Aged 12 to 17 Years

    • Phase 3
    • Ages 12 to 17
    • All sexes
    Sponsor
    AbbVie
    Study site
    Advanced Research Center /ID# 270257
    Registry record
    NCT06810505 · updated
  4. A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine

    • Phase 3
    • Ages 6 to 17
    • All sexes
    Sponsor
    AbbVie
    Study site
    Advanced Research Center /ID# 251381
    Registry record
    NCT05711394 · updated
  5. Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17)

    • Phase 3
    • Ages 6 to 17
    • All sexes
    Sponsor
    AbbVie
    Study site
    Advanced Research Center /ID# 227962
    Registry record
    NCT05125302 · updated

Source: ClinicalTrials.gov. Data processed . See every migraine study recruiting in Anaheim, CA on ClinicalTrials.gov.

Ask about studies near Anaheim

Tell us what you are looking for and a coordinator will contact you to talk through your options. Asking does not commit you to anything.

How should we reach you?
Add a message or the best time to reach you (optional)

Please do not include detailed medical information.

Before you contact a study

More locations in California

About these listings

These listings come from ClinicalTrials.gov, the study registry run by the U.S. National Library of Medicine. The data were processed on November 17, 2026. We show part of each public record (its title, phase, sponsor, basic eligibility and sites in this area) exactly as registered, and we group studies by place. Nothing in a record is reworded. This site lists only studies that test a medication, as each study is coded in the registry.

CNS Medication Trials does not run these studies and is not affiliated with their sponsors. A listing is not a recommendation, and only a study's own team can tell you whether you may be eligible. Follow the link on any study to read its full record and contact that team directly, or ask us and a coordinator will help you understand your options. How we source and check what we publish.

Sources and further reading

Ask about a study

A coordinator will contact you. Asking does not commit you to anything.

Call (888) 927-5768

or send a short form

How should we reach you?

Call